COVID-19: Terapi Penghambat IL-1 dan IL-6

Hendra H

Abstract


Abstract: As of February 2021, there are 102,817,575 cases of COVID-19 globally, causing 2,227,420 deaths, and has been declared as pandemic by WHO. Over time, the management of COVID-19 has evolved, namely the use of Interleukin (IL). Patients with severe COVID-19 experience a hyper-inflammatory response to the virus, called "cytokine storms". Cytokine storms are thought to occur due to the excessive release of pro-inflammatory cytokines such as IL-1?, IL-6, IL-18 and interferon-?. In hyperinflammatory conditions, therapy with cytokine-blocking agents such as IL-1 inhibitors (Anakinra) and IL-6 inhibitors (Tocilizumab) is quite promising. Anakinra has the effect of lowering il-6 production, its because IL-1 is a potential inducer for IL-6, so the Tocilizumab effect is also seen in Anakinra. Anakinra has a short half-life, so the undesirable effect can stop immediately. However, interleukin therapy still requires further research related to the efficacy and safety of the drug.

Keywords: COVID-19, IL-1 inhibitor, IL-6 inhibitor, Anakinra ,Tocilizumab


Keywords


: COVID-19, IL-1 inhibitor, IL-6 inhibitor, Anakinra ,Tocilizumab

References


DAFTAR PUSTAKA

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus. NEJM. 2020. DOI: 10.1056/NEJMoa2002032.

Cavalli G, Larcher A, Tomelleri A, Campochiaro C, Torre E.D., Luca G.D., et al. Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. The Lancet. 2021. DOI:https://doi.org/10.1016/S2665-9913(21)00012-6

Tim COVID-19. Pedoman tatalaksana COVID-19. Edisi 2. Jakarta. 2020.

Zhang Y, Zhong Y, Pan L, Dong J. Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far? Drug Discoveries & Therapeutics. 2020. DOI: 10.5582/ddt.2020.03006

Tim COVID-19. Pedoman tatalaksana COVID-19. Edisi 3. Jakarta. 2020.

Kooistra E.J., Waalders N.J.B., Grondman I, Janssen N.A.F., Nooijer A.H., Netea M.G., et al. Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study. Critical care.2020. https://doi.org/10.1186/s13054-020-03364-w.

Balkhair A, Zakwani I., Busaidi M, Naamani Z, Nazar Z, Balkhair O, et al. Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study. International Journal of Infectious Disease. 2020. DOI:https://doi.org/10.1016/j.ijid.2020.11.149.

Nasonov E, Samsonov M. The role of Interleukin 6 inhibitors in therapy of severe COVID-19. Biomedicine and Pharmacotherapy, 2020 Vol.131. https://doi.org/10.1016/j.biopha.2020.110698.

Han Q, Guo M, Zheng Y, Zhang Y, De Y, Xu C, et al. Current Evidence of Interleukin-6 Signaling Inhibitors in Patients With COVID-19: A Systematic Review and Meta-Analysis. Front. Pharmacol., 15 December 2020. https://doi.org/10.3389/fphar.2020.615972

Veerdonk F.L., Netea M.G. Blocking IL-1 prevent respiratory failure in COVID-19. Critical Care. July 2020. https://doi.org/10.1186/s13054-020-03166-0

Coomes E.A., Haghbayan H. Interleukin-6 in COVID-19: a systemic review and meta-analysis. med Rxiv. (2020), 10.1101/2020.03.30.200448058

C. Wu, X. Chen, Y. Cai, et al.Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.JAMA Intern Med., 180 (7) (2020), pp. 1-11, 10.1001/jamainternmed.2020.0994

M. Aziz, R. Fatima, R. Assaly. 2020. Elevated interleukin-6 and severe COVID-19: A meta-analysis . J Med Virol. (2020), 10.1002/jmv.25948

X. Xu, M. Han, T. Li, et al.2020. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A., 117 (20) (2020), pp. 10970-10975, 10.1073/pnas.2005615117

Du P, Geng J, Wang F, Chen X, Huang Z, Wang Y. Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome. Int J Med Sci 2021. doi:10.7150/ijms.53564.

Toniati P, Piva S, Cattalini M. et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020;19(7):102568.

Roche provides an update on the phase III COVACTA trial of Actemra/Roactenra in hospitalized patients with severe COVID 19 associated pneumonia. Accessed 08/02/2021.




DOI: https://doi.org/10.30596/jih.v2i1.6338

Refbacks

  • There are currently no refbacks.


 

Fakultas Kedokteran

Universitas Muhammadiyah Sumatera Utara
Jln.Gedung Arca No. 53 Medan 20217
Telp/HP/Whatsapp: +62 8112570085, +62 857-6248-0974
Website : http://jurnal.umsu.ac.id/index.php/JIH/index
Email : implementahusada@umsu.ac.id